Idronoxil and urogenital cancers. Noxopharm CEO Blog March 2017

March 30th, 2017 by Blog Author

Our last announcement (27th March) reported on two developments. Both relating to some research being done under contract for Noxopharm by Monash University and partially funded by the Federal Government. First development:   idronoxil-C  Q. What is idronoxil-C? A.  Idronoxil-C is an exciting development that we believe has increased very considerably the value of the Company’s […]

Read More

CEO Blog: Why there is good reason to be excited by the word ‘Abscopal’

March 6th, 2017 by Blog Author

Our primary focus remains to bring NOX66 to market to make both chemotherapy and radiotherapy work better and at lower, safer dosages. However, we now can reveal a tantalizing opportunity that is being incorporated into our trials for minimal additional cost. Last Friday’s announcement introduced that opportunity, as well as a new word for most […]

Read More